Analysis of the correlation between tumor and blood lipids and research progress of lipid-lowering drugs in tumor
MAO Xueyang1 GU Ning2 HU Hairui1 WEI Tianyi1 LI Zhigang2
1.School of Acupuncture and Massage, Henan University of Chinese Medicine, Henan Province, Zhengzhou 450046, China;
2.Department of Oncology, the Third Affiliated Hospital of Henan University of Chinese Medicine, Henan Province, Zhengzhou 450008, China
Abstract：After reviewing a large number of domestic and foreign literatures, triglycerides, total cholesterol, and low density lipoprotein cholesterol are found to be positively correlated with the occurrence and development risks of many tumors, and negatively correlated with the occurrence and development risks of a few tumors. Different studies have revealed inconsistent results of the correlation between the occurrence and development risk of tumor and triglyceride. However, high density lipoprotein cholesterol is negatively correlated with the occurrence and development risk of tumor. There have been basic and applied studies on statins, beta, cholesterol absorption inhibitors, antioxidant-probucol, pre-protein converting enzyme subtilisin inhibitor, nicotinic acid, and other chemical and traditional Chinese medicine lipid-lowering drugs in tumor treatment, and preliminary study on their target and mechanism. This paper found that the occurrence and development of tumors are closely related to the level of blood lipids, and the mechanism of the anti-tumor effect of lipid-lowering drugs needs further study.
毛雪杨1 谷宁2 胡海瑞1 魏天怡1 李志刚2. 肿瘤与血脂相关性分析及降脂药在肿瘤中的研究进展[J]. 中国医药导报, 2023, 20(10): 45-49.
MAO Xueyang1 GU Ning2 HU Hairui1 WEI Tianyi1 LI Zhigang2. Analysis of the correlation between tumor and blood lipids and research progress of lipid-lowering drugs in tumor. 中国医药导报, 2023, 20(10): 45-49.
[1] 王坤英.血脂水平与乳腺癌骨转移发生的相关性研究[J].中国药物与临床，2017，17（7）：3.
[2] 李道亮.术前CRP、血脂、肿瘤标志物与结直肠癌病理分期及预后的相关性研究[D].海口：海南医学院，2020.
[3] 孙无悔.血脂水平与胰腺癌发病风险、临床特征及术后短期结局关系研究[D].杭州：浙江大学，2018.
[4] 刘丽.乳腺癌的发生及其病理学特征与血脂水平相互关系的临床研究[D].长春：吉林大学，2019.
[5] Ulmer H，Borena W，Rapp K，et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria [J]. Br J Cancer，2009，101（7）：1202-1206.
[6] Tulinius H，Sigfússon N，Sigvaldason H，et al. Risk factors for malignant diseases：a cohort study on a population of 22 946 icelanders [J]. Cancer Epidemiol Biomarkers Prev，1997， 6（11）：863-873.
[7] Jiang Q，Wang L，Jin M，et al. The clinical value of lipid abnormalities in early stage cervical cancer [J]. Int J Gen Med，2022，15：3903-3914.
[8] Kitahara CM，De González AB，Freedman ND，et al. Total cholesterol and cancer risk in a large prospective study in Korea [J]. J Clin Oncol，2011，29（12）：1592-1598.
[9] Zhou P，Li B，Liu B，et al. Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors：a systematic review and meta-analysis [J]. Clin Chim Acta，2018，477：94-104.
[10] Mondul AM，Clipp SL，Helzlsouer KJ，et al. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE Ⅱ cohort [J]. Cancer Causes Control，2010，21（1）：61-68.
[11] Jafri H，Alsheikh-Ali AA，Karas RH. Baseline and on- treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy [J]. J Am Coll Cardiol，2010，55（25）：2846-2854.
[12] Wang Y，Sun X，Lin H，et al. Correlation between immune signature and high-density lipoprotein cholesterol level in stage Ⅱ/Ⅲ colorectal cancer [J]. Cancer Med，2019，8（3）：1209-1217.
[13] Pedersen KM，?覶olak Y，Bojesen SE，et al. Low high-density lipoprotein and increased risk of several cancers：2 population-based cohort studies including 116 728 individuals [J]. J Hematol Oncol，2020，13（1）：1-11.
[14] Beeghly-Fadiel A，Khankari NK，Delahanty RJ，et al. A Mendelian randomization analysis of circulating lipid traits and breast cancer risk [J]. Int J Epidemiol，2020，49（4）：1117-1131.
[15] Hao F，Chen J，Wu J，et al. Expression of serum sLOX-1 in patients with non-small-cell lung cancer and its correlation with lipid metabolism [J]. Can Respir J，2022，2022：6619331.
[16] Guan X，Liu Z，Zhao Z，et al. Emerging roles of low-density lipoprotein in the development and treatment of breast cancer [J]. Lipids Health Dis，2019，18（1）：1-9.
[17] Graaf MR，Richel DJ，van Noorden CJF，et al. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer [J]. Cancer Treat Rev，2004， 30（7）：609-641.
[18] Li IH，Shih JH，Tsai CS，et al. Inverse association of fibrates and liver cancer：a population-based case-control study in Taiwan [J]. J Clin Pharmacol，2019，59（9）：1170- 1176.
[19] Jiao HL，Zhao BL. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms [J]. Toxicol Appl Pharmacol，2002， 185（3）：172-179.
[20] Zhang N，Chu ES，Zhang J，et al. Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway [J]. Oncotarget，2014，5（18）：8330-8340.
[21] Chandran K，Goswami S，Sharma-Walia N. Implications of a peroxisome proliferator-activated receptor alpha （PPARα） ligand clofibrate in breast cancer [J]. Oncotarget，2016，7（13）：15577-15599.
[22] Salvo F，Bazin F，Kostrzewa A，et al. Fibrates and risk of cancer in tissues with high PPAR-α concentration：a nested case-control study [J]. Drug Saf，2014，37（5）：361-368.
[23] Miura K，Ohnishi H，Morimoto N，et al. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet [J]. Cancer Sci，2019，110（2）：771-783.
[24] Huang J，Li H，Wang X，et al. Impacts of ezetimibe on risks of various types of cancers：a meta-analysis and systematic review [J]. Eur J Cancer Prev，2023，32（1）：89-97.
[25] Kobber?覬 Lauridsen B，Stender S，Frikke-Schmidt R，et al. Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer [J]. Int J Epidemiol，2017，46（6）：1777-1785.
[26] Nishimura G，Yanoma S，Mizuno H，et al. An antioxidant，probucol，induces anti-angiogenesis and apoptosis in athymic nude mouse xenografted human head and neck squamous carcinoma cells [J]. Jpn J Cancer Res，1999，90（11）：1224-1230.
[27] Chuang LY，Guh JY，Ye YL，et al. Effects of probucol on cell proliferation in human ovarian cancer cells [J]. Toxicol Res （Camb），2016，5（1）：331-339.
[28] Iqbal M，Okazaki Y，Okada S. Probucol modulates iron nitrilotriacetate （Fe-NTA）-dependent renal carcinogenesis and hyperproliferative response：diminution of oxidative stress [J]. Mol Cell Biochem，2007，304（1）：61-69.
[29] Ko?觭 A，Karabay AZ，Yaprak A，et al. Effect of probucol on proliferation of leukemia，multiple myeloma，lymphoma，and fibroblast cells [J]. Turk J Pharm Sci，2021，18（1）：75-79.
[30] Abdelwahed KS，Siddique AB，Mohyeldin MM，et al. Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor [J]. Pharmacol Res，2020，158：104847.
[31] Xie M，Yu X，Chu X，et al. Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer [J]. Thorac Cancer，2022，13（3）：353-360.
[32] 韩晓燕，卫洪波，连建学，等.绞股蓝总甙对大鼠实验性高脂血症的影响[J].河南医学研究，1996，5（2）：113-116.
[33] 杜小燕，侯颖，覃华，等.绞股蓝多糖的抗肿瘤作用及其机制研究[J].科学技术与工程，2009，9（20）：5968-5972.
[34] 崔伟业.壮药国虾薄（绞股蓝）皂苷抗肿瘤作用及对胆固醇影响[D].北京：中央民族大学，2021.
[35] 陈萍，李朋，张浩.栀子黄色素与栀子苷降血脂和体内抗氧化作用的比较[J].华西药学杂志，2016，31（3）：254- 256.
[36] 石若夫，李大力，田春宇，等.栀子多糖的抗肿瘤活性研究[J].林产化学与工业，2002，22（4）：67-70.
[37] 邹毅，周敏.雀舌栀子二萜类化学成分提取及其抗肿瘤活性研究[J].江西化工，2019（5）：107-108.
[38] 李元青，马成杰，陈信义.三七活性成分抗肿瘤作用及其免疫学机制初探[J].现代中医临床，2008，15（1）：17- 19.
[39] 王茜，林焕冰，程玉芳，等.淫羊藿苷对高脂血症大鼠粘附分子基因表达的影响[J].中国动脉硬化杂志，2008， 16（1）：4-6.
[40] 李贵新，张玲.淫羊藿甙诱导肿瘤细胞凋亡及其机制的研究[J].中国肿瘤生物治疗杂志，1999，6（2）：131-135.
[41] 胡吉梦，姜昊文.淫羊藿素及相关衍生物的抗肿瘤机制研究进展[J].上海中医药杂志，2018，52（4）：107-112.
[42] 蔡宝祥，谢梅林，顾振纶.正交设计分析丹参和山楂不同提取物对血脂影响的交互作用[J].中草药，2004，35（2）：78-80.
[43] 张妍，李厚伟，孙建平，等.山楂果总黄酮的提取分离及体外抗肿瘤活性[J].中草药，2004，35（7）：787-789.
[44] 颜腾龙.八种药食同源中药降血脂和抗氧化作用研究[D].长沙：湖南农业大学，2014.
[45] 郝钦，谭晓慧，王飞，等.莱菔子抑制结肠癌干细胞恶性行为的研究[J].中华中医药学刊，2020，38（10）：154-156.
京公网安备 11010502046598号